September Luncheon with the Experts in New York City — Carcinoid and Neuroendocrine Tumor Patients Are Invited!

August 16, 2015

Carcinoid and neuroendocrine tumor (NET) patients are invited to join three medical experts for Lunch with the Experts in New York City on Sunday, September 27, 2015 at 12:30 pm. This special program was initiated and is sponsored by the Big Apple NETs

READ MORE

New Survey for the Carcinoid and Neuroendocrine Tumor Community

August 14, 2015

The Carcinoid Cancer Foundation is always looking at ways of improving content and services available to people living with carcinoid cancer and other neuroendocrine tumors and we are working with a pharmaceutical partner, Ipsen, to better understand…

READ MORE

Lexicon’s Carcinoid Syndrome Treatment Meets Primary Endpoint in Phase III Clinical Trial

August 5, 2015

Lexicon Pharmaceuticals Inc. has announced that the pivotal phase III clinical trial, TELESTAR, of its oral drug candidate telotristat etiprate met the primary endpoint in treating cancer patients with carcinoid syndrome that is not adequately controlled…

READ MORE

Call for Nominations: 6th Annual Warner Advocacy Award

July 30, 2015

Do you know someone who is a passionate advocate for patients with neuroendocrine tumors (NETs)? Novartis Oncology and The NET Alliance are searching for an outstanding NET patient advocate to recognize and honor with the 6th Annual Warner Advocacy

READ MORE
In Memoriam: Edda Gomez-Panzani, MD

In Memoriam: Edda Gomez-Panzani, MD

July 9, 2015

It is with deep sorrow that we learned of the passing of Edda Gomez-Panzani, MD on June 30, 2015. The NorCal CarciNET Community shared a tribute to Edda who “was instrumental in gaining FDA approval for Somatuline (lanreotide) for NETs patients …

READ MORE

Did I Take It . . . or Didn’t I?

July 7, 2015

When it comes to taking pills, drops, injections, and other forms of medication, about one third to one half of U.S. patients do not adhere to prescribed medication regimens (Osterberg and Blaschke, Adherence to Medication, New England Journal of Medicine,…

READ MORE

10 Highlights for the Carcinoid and Neuroendocrine Tumor Community

June 12, 2015
  • PET/CT using Gallium-68 DOTATOC captures hidden source of neuroendocrine cancer. “An investigational molecular imaging technique could be the key to finding the elusive primary tumor, say presenters at the 2015 Annual Meeting of the Society
READ MORE
Clinical Trial Rider Insurance Policy from Golden Rule

DENIED: Michael Farris’ Journey with Insurance for Neuroendocrine Cancer Treatment

June 8, 2015

The good news is the very positive result at the end – but the road to getting insurance coverage for Michael Farris’ participation in the PRRT (peptide receptor radionuclide therapy) clinical trial at Excel Diagnostics in Houston, Texas, was fraught…

READ MORE
Carcinoid/neuroendocrine cancer specialist Eric Liu, MD Joins Rocky Mountain Cancer Centers

9 More News Items for the Carcinoid and Neuroendocrine Cancer Community

May 19, 2015

Carcinoid/neuroendocrine cancer specialist Dr. Eric Liu will be joining the Rocky Mountain Cancer Centers in Denver, Colorado, effective June 1, 2015. He and medical oncologist Dr. Allen Cohn, also from Rocky Mountain Cancer Centers, will head up …

READ MORE
3rd Theranostics World Congress, The Clinician's Perspective, Thomas O'Dorisio, MD

15 Videos from the 3rd Theranostics World Congress

May 14, 2015

The 3rd Theranostics World Congress featured a patient education day on Saturday, March 14, made possible with support from the Carcinoid Cancer Foundation and the Caring for Carcinoid Foundation. The NorCal CarciNET Community provided funding to…

READ MORE